EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Mechanism of Action and Translational Potential of ( S )-Meclizine in Preemptive Prophylaxis Against Stroke

Jeong Hyun Lee iD, Vishal M Gohil iD, Pedram Heidari iD, Jessica L Seidel, Mohammad Zulkifli iD, Ying Wei, Yuhua Ji, Ali Daneshmand iD, Umar Mahmood iD, Clary B Clish iD, Vamsi K Mootha iD, Cenk Ayata iD

Stroke · 2024

DOI: 10.1161/strokeaha.123.044397 ↗

At a glance

Journal article in Stroke, 2024. Written by Jeong Hyun Lee and 11 co-authors. Institution: Neurovascular Research Unit, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown (J.H.L., P.H., J.L.S., Y.W.…. Major MEDLINE topics: Meclizine, Stroke. Cited 2 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIDDK NIH HHS, NINDS NIH HHS, Howard Hughes Medical Institute.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND: Mild chemical inhibition of mitochondrial respiration can confer resilience against a subsequent stroke or myocardial infarction, also known as preconditioning. However, the lack of chemicals that can safely inhibit mitochondrial respiration has impeded the clinical translation of the preconditioning concept. We previously showed that meclizine, an over-the-counter antivertigo drug, can toggle metabolism from mitochondrial respiration toward glycolysis and protect against ischemia-reperfusion injury in the brain, heart, and kidney. Here, we examine the mechanism of action of meclizine and report the efficacy and improved safety of the (S ) enantiomer. METHODS: We determined the anoxic depolarization latency, tissue and neurological outcomes, and glucose uptake using micro–positron emission tomography after transient middle cerebral artery occlusion in mice pretreated (−17 and −3 hours) with either vehicle or meclizine. To exclude a direct effect on tissue excitability, we also examined spreading depression susceptibility. Furthermore, we accomplished the chiral synthesis of (R )- and (S )-meclizine and compared their effects on oxygen consumption and histamine H1 receptor binding along with their brain concentrations. RESULTS: Micro–positron emission tomography showed meclizine increases glucose uptake in the ischemic penumbra, providing the first in vivo evidence that the neuroprotective effect of meclizine indeed stems from its ability to toggle metabolism toward glycolysis. Consistent with reduced reliance on oxidative phosphorylation to sustain the metabolism, meclizine delayed anoxic depolarization onset after middle cerebral artery occlusion. Moreover, the (S ) enantiomer showed reduced H1 receptor binding, a dose-limiting side effect for the racemate, but retained its effect on mitochondrial respiration. (S )-meclizine was at least as efficacious as the racemate in delaying anoxic depolarization onset and decreasing infarct volumes after middle cerebral artery occlusion. CONCLUSIONS: Our data identify (S )-meclizine as a promising new drug candidate with high translational potential as a chemical preconditioning agent for preemptive prophylaxis in patients with high imminent stroke or myocardial infarction risk.

Subjects

MeSH terms (MEDLINE)

MeclizineStrokeAnimalsMiceMaleInfarction, Middle Cerebral ArteryMice, Inbred C57BLBrainMitochondriaOxygen ConsumptionPositron-Emission Tomography

Author keywords

chemical preconditioningischemic injurymiddle cerebral artery occlusionneuroprotectionpreemptive prophylaxis

Substances

Meclizine

Authors and institutions

  • Neurovascular Research Unit, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown (J.H.L., P.H., J.L.S., Y.W., A.D., U.M., C.A.).
  • Therapeutics and Biotechnology Division, Korea Research Institute of Chemical Technology, Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon, South Korea (J.H.L.).
  • Department of Biochemistry and Biophysics, Texas A&M University, College Station (V.M.G., M.Z.).
  • Grace Science, LLC, Menlo Park, CA (Y.J.).
  • Broad Institute of MIT and Harvard, Cambridge, MA (C.B.C., V.K.M.).
  • Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston (V.K.M.).

ORCID profiles: Jeong Hyun Lee, Vishal M Gohil, Pedram Heidari, Mohammad Zulkifli, Ali Daneshmand, Umar Mahmood, Clary B Clish, Vamsi K Mootha, Cenk Ayata

Funding

  • NIDDK NIH HHS
  • NINDS NIH HHS
  • Howard Hughes Medical Institute
  • NIGMS NIH HHS
  • NCI NIH HHS

Cite

APA

Lee, J. H., Gohil, V. M., Heidari, P., Seidel, J. L., Zulkifli, M., Wei, Y., Ji, Y., Daneshmand, A., Mahmood, U., Clish, C. B., Mootha, V. K., & Ayata, C. (2024). Mechanism of Action and Translational Potential of ( S )-Meclizine in Preemptive Prophylaxis Against Stroke. Stroke. https://doi.org/10.1161/strokeaha.123.044397

Vancouver

Lee JH, Gohil VM, Heidari P, Seidel JL, Zulkifli M, Wei Y, et al. Mechanism of Action and Translational Potential of ( S )-Meclizine in Preemptive Prophylaxis Against Stroke. Stroke. 2024. doi:10.1161/strokeaha.123.044397

BibTeX
@article{Lee2024,
  author = {Lee, Jeong Hyun and Gohil, Vishal M and Heidari, Pedram and Seidel, Jessica L and Zulkifli, Mohammad and Wei, Ying and Ji, Yuhua and Daneshmand, Ali and Mahmood, Umar and Clish, Clary B and Mootha, Vamsi K and Ayata, Cenk},
  title = {Mechanism of Action and Translational Potential of ( S )-Meclizine in Preemptive Prophylaxis Against Stroke},
  journal = {Stroke},
  year = {2024},
  doi = {10.1161/strokeaha.123.044397}
}
Start for free →